Correction of the factors of cardiovascular risk in patients with type 2 diabetes
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The problem of correction of risk factors (RF) of cardiovascular dis ease (CVD), including such as C reactive protein (CRP) and uric acid (UA) in patients with type 2 diabetes mellitus (T2DM) is a particu larly topical issue of modern family medicine.
The aim of the study. To determine the efficacy and safety of atorvas tatin and losartan for the correction of CRP and UA in serum as a CVD risk factors in patients with T2DM.
Materials and methods. We have analyzed data of 112 patients with T2DM (52 women and 60 men, mean age 52.0 (48,0–59,8) years) with detection of RF of CVD. The dynamics of systolic blood pressure, blood biochemical parameters (lipidogram, high sensitivity CRP, UA) within 6 months was analyzed. Statistical analysis was performed using IBM SPSS Statistics 20.
Results. In the study, patients were divided into 2 groups: Group 1 – 31 patients with dyslipidemia and CRP levels in the blood serum of more than 3,0 mg/L, for which was assigned atorvastatin 10–20 mg per day, Group 2 – 20 patients with hypertension and levels of serum UA more than 300,0 mmol/L, for which was assigned losartan 100 mg per day. After 6 months revealed: receiving atorvastatin accompanied by decreasing of CRP levels on average by 33,0% and 64,5% of patients reached CRP levels less than 3,0 mg/L, and receiving losartan accom panied by decreasing of the level of serum UA on average by 29,0% and 60,0% of patients reached a level UA in serum of less than 300 mmol/L.
Conclusions. Due to its pleiotropic effects, atorvastatin reduces the amount of CRP and losartan – uric acid in the serum of patients with T2DM. The above mentioned requires further study in the order to improve.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Ендокринологія: Підручник / [Єфімов А.С., Боднар П.М., Большова Зубковська О.В. та ін.]; під ред. А.С. Єфімова. – К.: Вища школа, 2004. – С. 181–204.
Соломенчук .М. Можливості інкретинової терапії у лікуванні цукрового діабету 2-го типу: (міжрегіональне засідання членів Української діабетологічної асоціації та Турецької ендокринологічної асоціації) [Електронний ресурс] / Т.М. Соломенчук, Б.М. Маньковський // Український медичний часопис. – 2013. – Режим доступу до ресурсу: http: //www. umj. com. ua/ article/60722/mozhlivosti-inkretinovoi-terapii-u-likuvanni-cukrovogo-diabetu-2-go-tipu.
Defining and reporting hypoglycemia in diabetes. A report from the American Diabetes Association Workgroup on Hypoglycemia // Diabetes Care. – 2005. – Vol. 28, No. 5. – Р. 1245–1249..
Mora S. The clinical utility of High sensitivity C reactive protein in Cardiovascular disease and the potential implication of JUPITER on Current practice / Mora S, et al. // Guidelines clinical chemistry. – 2009. – Vol. 55. – P. 2219–2228..
Ridker P.M. C reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8 year follow up of 14719 initially healthy Am women. / Ridker P.M., Buring J.E., Cook N.R., Rifai N. // Circulation. – 2003. – Vol. 107. – Р. 391–397..
Cannon CP. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes / Cannon CP, et al. // The New England Journal of Medicine. – 2004. – Vol. 350 (15). – Р. 1495–1504..
Farmer JA. Clinical Trials and Surrogate End Points: Lessons From the ENHANCE Trial / John Alan Farmer // Future Lipidology. – 2008. – Vol. 3 (4). – Р. 353–357..
Liebson PR. PROVE IT and REVERSAL [Електронний ресурс] / Philip R. Liebson et al. // Prev Cardiol. – 2004. – Vol. 7 (3). – Режим доступу до ресурсу: http://www.med-scape.com/viewarticle/484048.
Ioachimescu AG. Serum uric acid is an independent predictor of all cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study / Ioachimescu A.G., Brennan D.M., Hoar B.M. et al. // Arthritis Rheum. – 2008. – Vol. 58, No. 2. – P. 623–30..
Lehto S. Serum uric acid is a strong predictor of stroke in patients with non–insulin dependent diabetes mellitus. / Lehto S, Niskanen L, Rönnemaa T, Laakso M. еt al. // Stroke. – 1998. – Vol. 29. – Р. 635–639..
Naritomi H. Efficacy and safety of long term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J HEALTH) study / Naritomi H., Fujita T., Ito S., Ogihara T. et al. // Hypertens. Res. – 2008. – Vol. 31, No. 2. – Р. 295–304..
